Clinical

High-flow nasal cannula oxygen compared to standard oxygen therapy is not associated with a significant reduction in mortality in patients with respiratory failure due to COVID-19 - The SOHO-Randomized Clinical Trial |  Medicine in 2 Minutes

High-flow nasal cannula oxygen compared to standard oxygen therapy is not associated with a significant reduction in mortality in patients with respiratory failure due to COVID-19 – The SOHO-Randomized Clinical Trial | Medicine in 2 Minutes

1. In this randomized controlled trial, among 711 patients with respiratory failure due to COVID-19, day 28 mortality was 10% in the high-flow oxygen group and 11% in the oxygen therapy group standard. 2. The intubation rate was significantly lower with high flow oxygen (45%) than with standard oxygen (53%). Level of evidence assessment: 1 …

High-flow nasal cannula oxygen compared to standard oxygen therapy is not associated with a significant reduction in mortality in patients with respiratory failure due to COVID-19 – The SOHO-Randomized Clinical Trial | Medicine in 2 Minutes Read More »

New Alzheimer's drug slows mental decline by 27% in clinical trial

New Alzheimer’s drug slows mental decline by 27% in clinical trial

Japanese pharmaceutical company Eisai and its partner, Cambridge-based Biogen, announced that their drug slowed cognitive decline in Alzheimer’s disease in a global trial. The drug, an antibody called lecanemab, slowed the rate of cognitive decline in volunteers by 27% compared to those given a placebo in the large late-stage trial. The companies plan to present …

New Alzheimer’s drug slows mental decline by 27% in clinical trial Read More »

Reflections from a Clinical Ethics Intern - Baylor College of Medicine Blog Network

Reflections from a Clinical Ethics Intern – Baylor College of Medicine Blog Network

This is the fourth in an ongoing series by Center for Medical Ethics and Health Policy summer interns, undergraduate and graduate students interested in emerging ethical issues. “How to become a clinical ethicist” is a phrase I’ve Googled more times than I’m willing to admit. My interest began after I attended a lecture on bioethics …

Reflections from a Clinical Ethics Intern – Baylor College of Medicine Blog Network Read More »

Quartet Health Adds National Clinical Leaders to Its Leadership Team to Strengthen the Company's Commitment to Quality Mental Health Care

Quartet Health Adds National Clinical Leaders to Its Leadership Team to Strengthen the Company’s Commitment to Quality Mental Health Care

NEW YORK, September 22, 2022 /PRNewswire/ — Quartet Health today announced two new strategic hires, reinforcing its commitment to providing unparalleled clinical expertise in mental health care: dr. Michael Lippe joins Quartet as Chief Medical Officer to oversee Quartet’s end-to-end clinical strategy as Quartet continues to advance integration between mental and physical healthcare. dr. Sherry …

Quartet Health Adds National Clinical Leaders to Its Leadership Team to Strengthen the Company’s Commitment to Quality Mental Health Care Read More »

Curebase and Meru Health Partner for Clinical Research of App-Based Mental Health Treatment Program

Curebase and Meru Health Partner for Clinical Research of App-Based Mental Health Treatment Program

SAN FRANCISCO, September 20, 2022 /PRNewswire/ — Curebase, a company committed to democratizing access to clinical studies, today announced its partnership with Meru Health in a three-year clinical trial to determine the program’s effectiveness. 12-week treatment program from online mental health provider to reduce depression among primary care patients. The Meru Health Program is an …

Curebase and Meru Health Partner for Clinical Research of App-Based Mental Health Treatment Program Read More »

Sandoz Announces Further Progress in its Biosimilars Portfolio, with the Publication of Positive Results from the Integrated Phase I/III Clinical Trial of Denosumab

Sandoz Announces Further Progress in its Biosimilars Portfolio, with the Publication of Positive Results from the Integrated Phase I/III Clinical Trial of Denosumab

The ROSALIA study met the primary endpoints, confirming that the proposed biosimilar denosumab matches the reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in postmenopausal women with osteoporosis Osteoporosis is responsible for 8.9 million bone fractures a year, including debilitating hip fractures – a number that is expected to rise dramatically over …

Sandoz Announces Further Progress in its Biosimilars Portfolio, with the Publication of Positive Results from the Integrated Phase I/III Clinical Trial of Denosumab Read More »